Endogenous hyperinsulinaemia and exogenous insulin: A common theme between atherosclerosis, increased cancer risk and other morbidities

Atherosclerosis

Volumn 222, Issue 1, 2012, Pages 26-28

  Holden, Sarah E ^a   Currie, Craig J ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Atherosclerosis; Cancer; Hyperinsulinaemia; Insulin; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; HEMOGLOBIN A1C; INSULIN; SULFONYLUREA;

ATHEROSCLEROSIS; CANCER RISK; CARDIOVASCULAR DISEASE; DRUG INFUSION; DRUG SAFETY; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

HUMANS; PLAQUE, ATHEROSCLEROTIC; RECEPTOR, INSULIN;

EID: 84859815404     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.01.052     Document Type: Note

References (33)

1. World Health Organization. Diabetes factsheet no. 312. August 2011. http://www.who.int/mediacentre/factsheets/fs312/en/index.html.
2. Holden S.H., Poole C.D., Morgan C.L., Currie C.J. Evaluation of the incremental cost to the National Health Service of prescribing analogue insulin. BMJ Open 2011, 2:e00025.
3. American Diabetes Association Standards of medical care in diabetes. Diabetes Care 2011, 34:S11-S61.
4. Colacayo D.C., Niu F., McCombs J.S., Cheetham T.C. A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study. Diabetes Care 2011, 34:77-83.
5. Mellbin L.G., Malmberg K., Norhammar A., Wedel H., Rydén L. Prognostic implications of glucose lowering treatment in patients with acute myocardial infarction and diabetes. Experiences from an extended follow of up the DIGAMI 2 study. Diabetologia 2011, 54:1308-1317. For the DIGAMI 2 Investigators.
6. Wright A.D., Cull C.A., Macleod K.M., Holman R.R. Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J Diabetes Complicat 2006, 20:395-401.
7. Nordin C. The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. Diabetologia 2010, 53:1552-1561.
8. Rensing K.L., Reuwer A.Q., Arsenault B.J., et al. Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing?. Diabetes Obes Metab 2011, 13:1073-1087.
9. Cao W., Ning J., Yang X., Liu Z. Excess exposure to insulin is the primary cause of insulin resistance and its associated atherosclerosis. Curr Mol Pharmacol 2011, 4:154-166.
10. Currie C.J., Peters J.R., Tynan A., et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 2010, 375:481-489.
11. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
12. Gerstein H.C., Miller M.E., Byington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
13. Patel A., MacMahon S., Chalmers J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
14. Duckworth W., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
15. The Action to Control Cardiovascular Risk in Diabetes study Group Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
16. Morgan CL, Jenkins-Jones S, Evans M, Barnett AH, Poole CD, Currie CJ. Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs. Diabetes, Obes Metab 2012, doi:10.1111/j.1463-1326.2011.01552.x.
17. Russell-Jones D., Khan R. Insulin-associated weight gain in diabetes - causes, effects and coping strategies. Diabetes Obes Metab 2006, 9:799-812.
18. Anderson J.W., Konz E.C. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res 2001, 9:326S-334S.
19. Donnelly L.A., Morris A.D., Frier B.M., et al. Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population-based study. Diabet Med 2005, 22:749-755.
20. Ott A., Stolk R.P., VAN Harskamp F., Pols H., Hofman A., Breteler M. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999, 53:137-142.
21. Monami M., Cresci B., Columbini A., et al. Bone fractures and hypoglycaemic treatment in type 2 diabetic patients. Diabetes Care 2008, 31:199-203.
22. Currie C.J., Poole C.D., Gale E.A.M. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009, 52:1766-1777.
23. Coughlin S.S., Calle E.E., Teras L.J., Petrelli J., Thun M.J. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004, 159:1160-1167.
24. Currie C.J., Poole C.D., Jenkins-Jones S., Gale E.A.M., Johnson J.A., Morgan C.L. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 2012, 35:299-304.
25. Gallagher E.M., LeRoith D. The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrin Metab 2010, 21:610-618.
26. Bowker S.L., Majumdar S.R., Veugelers P., Johnson J.A. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006, 29:254-258.
27. Yang Y.-X., Hennessy S., Lewis J.D. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004, 127:1044-1050.
28. Bowker S.L., Yasui Y., Veuglers P., Johnson J.A. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia 2010, 53:1631-1637.
29. Rensing KL, von der Thusen JH, Weijers EM, et al. Endothelial insulin receptor expression in human atherosclerotic plaques: linking micro- and macrovascular disease in diabetes? Atherosclerosis, in press. doi:10.1016/j.atherosclerosis.2012.01.035.
30. Gamble J.-H., Simpson S.H., Eurich D.T., Majumdar S.R., Johnson J.A. Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes Obes Metab 2010, 12:47-53.
31. Devindra S., Sudhish S., Tej S.S. Sulfonylureas: do we need to introspect safety again?. Expert Opin Drug Saf 2011, 10:851-861.
32. Taubes G. Unravelling the obesity-cancer connection. Science 2012, 335:28-32.
33. Currie C.J., Johnson J.A. The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern. Diabetes Obes Metab 2012, 14:1-4.